- The disease
- Acute graft-versus-host disease (aGvHD) is a life-threatening complication that can occur after a donor bone marrow or stem cell transplant, in which the donor's immune cells attack the recipient's tissues. In the steroid-refractory (SR) form, the disease does not respond to corticosteroids, which are the standard first-line treatment. Pediatric SR-aGvHD carries a high mortality rate and, until recently, had no FDA-approved treatment option (per the Ryoncil FDA prescribing information).
- What the asset is trying to do
- Remestemcel-L (Ryoncil) is an off-the-shelf allogeneic cell therapy consisting of mesenchymal stromal cells (MSCs) expanded from donor bone marrow and cryopreserved for ready use. MSCs are not thought to permanently engraft; instead they are understood to act transiently by releasing anti-inflammatory signals that modulate the overactive immune response driving GvHD (per the Ryoncil FDA prescribing information). This approach differs from conventional immunosuppressants, which broadly suppress immune activity, and from CAR-T therapies, which involve genetically engineered donor or patient T-cells.
- What the trial is measuring, and why it matters
- The pivotal study supporting approval evaluated overall response rate (ORR) at day 28 as the primary endpoint, with overall survival as a key secondary endpoint (per the Ryoncil FDA prescribing information). ORR in this context captures the proportion of patients whose GvHD showed a measurable reduction in severity. Survival endpoints are considered particularly meaningful in SR-aGvHD given the high mortality associated with the condition.
- Efficacy benchmarks in this setting
- Prior to Ryoncil's approval, SR-aGvHD in children lacked an FDA-approved therapy, making direct approved-comparator benchmarks limited. In published studies of ruxolitinib (a JAK inhibitor approved in adults with SR-aGvHD), overall response rates of approximately 57% at day 28 were reported in a predominantly adult population (per Zeiser et al, New England Journal of Medicine, 2020; NCT03112603). Remestemcel-L's pivotal trial enrolled pediatric patients, and the FDA noted in its December 2024 approval that the data supported efficacy in that population (per the Ryoncil FDA prescribing information); however, cross-trial comparisons of response rates are not statistically valid given differences in patient populations, trial design, and endpoints.